RECRUITING

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Talk to us

Conditions

Multiple MyelomaElranatamabPost Trial AccessRoll-over StudyExtension StudyMM-15MagnetisMM15BCMABCMA antibodyMagnetismBispecific antibodyElrexfio

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Official Title

ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES

Quick Facts

Study Start:2023-10-03
Study Completion:2031-02-22
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06057402

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants must agree to follow the reproductive criteria as outlined in the protocol
  2. * Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).
  1. * Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  2. * Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.

Contacts and Locations

Study Contact

Pfizer CT.gov Call Center
CONTACT
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com

Principal Investigator

Pfizer CT.gov Call Center
STUDY_DIRECTOR
Pfizer

Study Locations (Sites)

UC Irvine Health
Orange, California, 92868
United States
Franciscan Health
Indianapolis, Indiana, 46237
United States

Collaborators and Investigators

Sponsor: Pfizer

  • Pfizer CT.gov Call Center, STUDY_DIRECTOR, Pfizer

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-03
Study Completion Date2031-02-22

Study Record Updates

Study Start Date2023-10-03
Study Completion Date2031-02-22

Terms related to this study

Keywords Provided by Researchers

  • Multiple Myeloma
  • Elranatamab
  • Post Trial Access
  • Roll-over Study
  • Extension Study
  • MM-15
  • MagnetisMM15
  • BCMA
  • BCMA antibody
  • Magnetism
  • Bispecific antibody
  • Elrexfio

Additional Relevant MeSH Terms

  • Multiple Myeloma